{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 460123299
| IUPAC_name = (1''S'',2''S'',3''R'',4''S'',7''R'',9''S'',10''S'',12''R'',15''S'')-4-(Acetyloxy)-15-<nowiki/>{[(2''R'',3''S'')-3-<nowiki/>{[(tert-butoxy)carbonyl]amino}-2-hydroxy-3-phenylpropanoyl]oxy}-1-hydroxy-9,12-dimethoxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0<sup>3,10</sup>.0<sup>4,7</sup>]heptadec-13-en-2-yl benzoate
| image = Cabazitaxel.png
| alt =  

<!--Clinical data-->
| tradename = Jevtana
| Drugs.com = {{drugs.com|CDI|cabazitaxel}}
| MedlinePlus = a611009
| licence_EU = Jevtana
| licence_US = Cabazitaxel
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = D
| pregnancy_category =  
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled-->
| legal_CA = <!-- OTC, Rx-only, Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = POM
| legal_US = Rx-only
| legal_status =  
| routes_of_administration = Intravenous

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| IUPHAR_ligand = 6798
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 183133-96-2
| ATC_prefix = L01
| ATC_suffix = CD04
| PubChem = 9854073
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 63584
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB06772
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 8029779
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 51F690397J
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201748
| KEGG_Ref = {{keggcite|changed|kegg}}
| KEGG = D09755

<!--Chemical data-->
| C=45 | H=57 | N=1 | O=14 
| molecular_weight = 835.93 g/mol
| smiles = CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC)C)OC
| StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C45H57NO14/c1-24-28(57-39(51)33(48)32(26-17-13-11-14-18-26)46-40(52)60-41(3,4)5)22-45(53)37(58-38(50)27-19-15-12-16-20-27)35-43(8,36(49)34(55-10)31(24)42(45,6)7)29(54-9)21-30-44(35,
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = BMQGVNUXMIRLCK-OAGWZNDDSA-N
}}

'''Cabazitaxel''' (previously '''XRP-6258''', trade name '''Jevtana''') is a semi-synthetic derivative of a natural [[taxoid]].<ref>http://www.cancer.gov/drugdictionary/?CdrID=534131</ref> It was developed by [[Sanofi-Aventis]] and was approved by the U.S. [[Food and Drug Administration|FDA]] for the treatment of hormone-refractory [[prostate cancer]] on June 17, 2010. It is a [[microtubule]] inhibitor, and the fourth [[taxane]] to be approved as a [[cancer therapy]].<ref>{{cite press release
  | title = Jevtana (cabazitaxel) Injection Approved by U.S. FDA After Priority Review
  | publisher = sanofi-aventis
  | date = 2010-06-17
  | url = http://sanofi-aventis.mediaroom.com/index.php?s=43&item=288
  | accessdate = June 17, 2010  
}}</ref>{{rs|date=January 2015}}

Cabazitaxel in combination with [[prednisone]] is a treatment option for [[hormone-refractory prostate cancer]] following [[docetaxel]]-based treatment.

==Clinical trials==
In a [[Phases of clinical research#Phase III|phase III trial]] with 755 men for the treatment of [[castration-resistant prostate cancer]], median survival was 15.1 months for patients receiving cabazitaxel versus 12.7 months for patients receiving [[mitoxantrone]]. Cabazitaxel was associated with more grade 3–4 [[neutropenia]] (81.7%) than mitoxantrone (58%).<ref>{{cite web |url=http://professional.cancerconsultants.com/oncology_main_news.aspx?id=44709 |title=Cabazitaxel Effective for Hormone Refractory Prostate Cancer After Failure of Taxotere }}</ref>

==See also==
* [[Paclitaxel]]
* [[Docetaxel]]

==References==
{{reflist}}

== External links ==
* [http://www.jevtana.com Cabazitaxel] – Official web site of manufacturer.
* [http://products.sanofi-aventis.us/jevtana/jevtana.html Cabazitaxel Prescribing Information] – Official prescribing information.
* [http://druginfo.nlm.nih.gov/drugportal/dpdirect.jsp?name=Cabazitaxel U.S. National Library of Medicine: Drug Information Portal – Cabazitaxel]

{{Chemotherapeutic agents}}

[[Category:Microtubule inhibitors]]
[[Category:Mitotic inhibitors]]
[[Category:Carbamates]]
[[Category:Benzoates]]
[[Category:Acetate esters]]
[[Category:Taxanes]]

{{antineoplastic-drug-stub}}